Christina Gayle Tise

Dr. Christina Gayle Tise

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in Genetics in Medicine
Verified
Journal Article
Closed access
SCSabina Cook
Sabina Cook
EDEmily Dunn
Emily Dunn
JKJenna Kornish
Jenna Kornish
LCLaurel Calderwood
Laurel Calderwood
MCMaryAnn Campion
MaryAnn Campion
CTChristina Gayle Tise
Christina Gayle Tise

1 September 2016 in G3: Genes, Genomes, Genetics
Verified
Journal Article
Open access
PDF file
CTChristina Gayle Tise
Christina Gayle Tise
JPJames A Perry
James A Perry
LALeslie E Anforth
Leslie E Anforth
MPMary A Pavlovich
Mary A Pavlovich
JBJoshua D. Backman
Joshua D. Backman
ASAlan R. Shuldiner
Alan R. Shuldiner
Using genomic applications to glean insights into human biology, we systematically searched for nonsense, single nucleotide variants (SNVs) that are rare in the general population but enriched in the Old Order Amish (Amish) due to founder effect. We identified two non-linked, nonsense SNVs (R12X and W48X) in SLC13A1 (allele frequencies 0.29% and 0.74% in the Amish; enriched 1.2-fold and 3.7-fold, compared to the outbred Caucasian population, respectively). SLC13A1 encodes the apical, sodium-sulfate cotransporter (NaS1) responsible for sulfate (re)absorption in the kidneys and intestine. Both SLC13A1 R12X and W48X were independently associated with a 27.6% (P=2.7x10-8) and 27.3% (P=6.9x10-14) decrease in serum sulfate, respectively (P=8.8x10-20 for carriers of either SLC13A1 nonsense SNV). We further performed the first exome- and genome-wide association study (ExWAS/GWAS) of serum sulfate and identified a missense variant (L348P) in SLC26A1, which encodes the basolateral sulfate-anion transporter (Sat1), that was associated with decreased serum sulfate (P=4.4x10-12). Consistent with sulfate’s role in xenobiotic detoxification and protection against acetaminophen-induced hepatotoxicity, SLC13A1 nonsense SNV carriers had higher aminotransferase levels compared to non-carriers. Furthermore, SLC26A1 L348P was associated with lower whole-body bone mineral density (BMD) and higher serum calcium, consistent with the osteochondrodysplasia exhibited by dogs and sheep with naturally-occurring, homozygous, loss-of-function mutations in Slc13a1. This study demonstrates the power and translational potential of systematic identification and characterization of rare, loss-of-function variants and warrants additional studies to better understand the importance of sulfate in human physiology, disease, and drug toxicity.

8 March 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
CTChristina Gayle Tise
Christina Gayle Tise
CVCourtney P. Verscaj
Courtney P. Verscaj
BMBryce A. Mendelsohn
Bryce A. Mendelsohn
JWJeremy Woods
Jeremy Woods
CLChung U. Lee
Chung U. Lee
KCKristina P. Cusmano‐Ozog
Kristina P. Cusmano‐Ozog

8 March 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
CTChristina Gayle Tise
Christina Gayle Tise
JMJose Andres Morales
Jose Andres Morales
ALAriel S. Lee
Ariel S. Lee
FVFrances Velez‐Bartolomei
Frances Velez‐Bartolomei
Brendan FloydBrendan Floyd
Brendan Floyd
GEGregory M. Enns
Gregory M. Enns

25 June 2025 in Fertility and Sterility
Verified
Journal Article
Closed access
CTChristina Gayle Tise
Christina Gayle Tise
KVKajal Verma
Kajal Verma
GRGreysha Rivera-Cruz
Greysha Rivera-Cruz
SCSolmaz Chamanara
Solmaz Chamanara
SGSara K. Gerber
Sara K. Gerber
RLRuth B. Lathi
Ruth B. Lathi

26 June 2024 in Genes
Verified
Journal Article
Open access
PDF file
CBCarlos Francisco Mares Beltran
Carlos Francisco Mares Beltran
CTChristina Gayle Tise
Christina Gayle Tise
RBRebekah Barrick
Rebekah Barrick
ANAnnie D. Niehaus
Annie D. Niehaus
RSRebecca Sponberg
Rebecca Sponberg
JAJose E Abdenur
Jose E Abdenur
The state of California (CA) added X-linked adrenoleukodystrophy (X-ALD) to newborn screening (NBS) in 2016 via the measurement of C26:0-lysophosphatidylcholine (C26:0-LPC) in a two-tier fashion, followed by sequencing of the ABCD1 gene. This has resulted in the identification of individuals with genetic conditions beyond X-ALD that can also result in elevated C26:0-LPC by NBS. We describe the biochemical, molecular, and clinical characteristics of nine patients from two metabolic centers in California who screened positive by NBS for elevated C26:0-LPC between 2016 and 2022 and were ultimately diagnosed with a genetic condition other than X-ALD. Seven individuals were diagnosed with Zellweger spectrum disorder (ZSD) due to biallelic variants in PEX genes. One male was diagnosed with Klinefelter syndrome and one female was found to have an X chromosome contiguous gene deletion syndrome after the identification of a heterozygous VUS and hemizygous VUS variant in ABCD1, respectively. Patients with ZSD had significantly higher first- and second-tier C26:0-LPC levels compared to the two non-ZSD cases. Identification of children with ZSD and atypical patterns of ABCD1 variants is a secondary benefit of NBS for X-ALD, leading to earlier diagnosis, prompt therapeutic initiation, and more accurate genetic counseling. As screening for X-ALD continues via the measurement of C26:0-LPC, our knowledge of additional genetic conditions associated with elevated C26:0-LPC will continue to advance, allowing for increased recognition of other genetic disorders for which early intervention is warranted.